Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Duff

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|July 1, 2015
A Missed OpportunityLeon Rozen, Kim Duff, Catherine Taggart, et al.
Journal of Clinical Immunology|June 19, 2024
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy ParticipantsZhaoyang Li, Andras Nagy, Dirk Lindner, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|March 12, 2025
Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's RoleKim Duff, Arianna Soresini, Nancy Wolf, et al.
Journal of the Peripheral Nervous System : JPNS|November 11, 2024
Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trialRobert D M Hadden, Henning Andersen, Vera Bril, et al.
Journal of the Peripheral Nervous System : JPNS|June 14, 2023
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trialVera Bril, Robert D M Hadden, Thomas H Brannagan, et al.
European Journal of Neurology|April 18, 2025
The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating PolyradiculoneuropathyMamatha Pasnoor, Colin Anderson-Smits, Todd Levine, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|July 1, 2015
A Missed OpportunityLeon Rozen, Kim Duff, Catherine Taggart, et al.
Journal of Clinical Immunology|June 19, 2024
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy ParticipantsZhaoyang Li, Andras Nagy, Dirk Lindner, et al.
Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society|March 12, 2025
Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's RoleKim Duff, Arianna Soresini, Nancy Wolf, et al.
Journal of the Peripheral Nervous System : JPNS|November 11, 2024
Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trialRobert D M Hadden, Henning Andersen, Vera Bril, et al.
Journal of the Peripheral Nervous System : JPNS|June 14, 2023
Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trialVera Bril, Robert D M Hadden, Thomas H Brannagan, et al.
European Journal of Neurology|April 18, 2025
The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating PolyradiculoneuropathyMamatha Pasnoor, Colin Anderson-Smits, Todd Levine, et al.
Pageof 1